• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Which is the Optimal Preoperative Systemic Chemotherapy Regimen for Patients with Peritoneal Metastases from Colorectal Cancer?

作者信息

Kepenekian Vahan, Kefleyesus Amaniel, Passot Guillaume, Rousset Pascal, Benzerdjeb Nazim, You Benoit, Peron Julien, Glehen Olivier

机构信息

Surgical Oncology Department, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Bénite, France.

EA3738 CICLY, Université Claude Bernard Lyon 1 (UCBL1), Lyon, France.

出版信息

Ann Surg Oncol. 2023 Jun;30(6):3316-3317. doi: 10.1245/s10434-023-13214-y. Epub 2023 Feb 8.

DOI:10.1245/s10434-023-13214-y
PMID:36752969
Abstract
摘要

相似文献

1
ASO Author Reflections: Which is the Optimal Preoperative Systemic Chemotherapy Regimen for Patients with Peritoneal Metastases from Colorectal Cancer?ASO作者反思：结直肠癌腹膜转移患者的最佳术前全身化疗方案是什么？
Ann Surg Oncol. 2023 Jun;30(6):3316-3317. doi: 10.1245/s10434-023-13214-y. Epub 2023 Feb 8.
2
ASO Author Reflections: HIPEC Immunogenic Changes Could be Further Exploited by Immunotherapy to Treat Peritoneal Metastases from Colorectal Cancer.ASO作者反思：热灌注化疗的免疫原性变化可通过免疫疗法进一步利用，以治疗结直肠癌的腹膜转移。
Ann Surg Oncol. 2023 May;30(5):2664-2665. doi: 10.1245/s10434-023-13254-4. Epub 2023 Feb 17.
3
ASO Author Reflections: Fragmented Care in Patients with Peritoneal Metastases.ASO作者反思：腹膜转移患者的碎片化护理
Ann Surg Oncol. 2024 Jan;31(1):655-656. doi: 10.1245/s10434-023-14400-8. Epub 2023 Oct 6.
4
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.ASO作者反思：结直肠癌腹膜转移的发病时间并非是经细胞减灭术联合腹腔内热化疗后生存结局的独立预测因素。
Ann Surg Oncol. 2022 Oct;29(11):6577-6578. doi: 10.1245/s10434-022-11842-4. Epub 2022 Apr 29.
5
ASO Author Reflections: Neoadjuvant Systemic Chemotherapy in Isolated Resectable Colorectal Peritoneal Metastases: Ready for Standard of Care?ASO作者反思：孤立可切除的结直肠癌腹膜转移中的新辅助全身化疗：是否已准备好成为护理标准？
Ann Surg Oncol. 2022 Oct;29(11):6632-6633. doi: 10.1245/s10434-022-11749-0. Epub 2022 Apr 12.
6
ASO Author Reflections: Biopsychosocial Late Effects are Frequent and Negatively Impact Quality of Life Following Curatively Intended Surgery for Colorectal and Appendiceal Cancer with Peritoneal Metastases.美国外科医师学会作者反思：对于患有腹膜转移的结直肠癌和阑尾癌进行根治性手术后，生物心理社会晚期效应很常见，且对生活质量有负面影响。
Ann Surg Oncol. 2024 Mar;31(3):1696-1697. doi: 10.1245/s10434-023-14727-2. Epub 2023 Dec 10.
7
ASO Author Reflections: Combination Intra-Peritoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastases.ASO作者反思：腹腔内与全身联合化疗用于治疗伴有腹膜转移的胃癌
Ann Surg Oncol. 2022 Dec;29(13):8606-8607. doi: 10.1245/s10434-022-12102-1. Epub 2022 Oct 3.
8
ASO Author Reflections: Preoperative Serological Biomarkers as Novel Prognostic Factors in Patients with Peritoneal Metastases of Colorectal Cancer Origin.ASO作者反思：术前血清生物标志物作为结直肠癌源性腹膜转移患者的新型预后因素
Ann Surg Oncol. 2023 Mar;30(3):1870-1871. doi: 10.1245/s10434-022-12771-y. Epub 2022 Nov 6.
9
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).围手术期全身治疗联合细胞减灭术和 HIPEC 对比单纯 HIPEC upfront 细胞减灭术治疗孤立可切除结直肠腹膜转移瘤：一项多中心、开放标签、平行组、Ⅱ-Ⅲ 期、随机、优效性研究（CAIRO6）方案。
BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.
10
ASO Author Reflections: If Once Is Good, Is Twice Just as Good? A critical evaluation of Repeat CRS-HIPEC for Colorectal Peritoneal Metastases.ASO作者反思：一次有益，两次是否同样有益？对复发性CRS-HIPEC治疗结直肠癌腹膜转移的批判性评估
Ann Surg Oncol. 2021 Sep;28(9):5339-5340. doi: 10.1245/s10434-021-09704-6. Epub 2021 Feb 18.

本文引用的文献

1
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.可切除结直肠腹膜转移的围手术期全身治疗与单独细胞减灭术和腹腔热灌注化疗的比较：一项 2 期随机临床试验。
JAMA Surg. 2021 Aug 1;156(8):710-720. doi: 10.1001/jamasurg.2021.1642.
2
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.细胞减灭术联合腹腔热灌注化疗与单纯细胞减灭术治疗结直肠腹膜转移瘤（PRODIGE 7）：一项多中心、随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18.
3
Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review.可切除结直肠腹膜转移瘤的围手术期全身治疗：广泛应用的充分证据？一项批判性系统评价
Crit Rev Oncol Hematol. 2017 Jun;114:53-62. doi: 10.1016/j.critrevonc.2017.03.028. Epub 2017 Mar 24.